Fractyl Health Inc. (GUTS)
GUTS trades on Nasdaq in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1572616/000119312526121793/0001193125-26-121793-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | GUTS on Nasdaq |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001572616 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$141.0M |
| Operating income | -$96.8M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $81.5M |
| Total assets | $121.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Management intends to mitigate the conditions and events that raise substantial doubt about the Company's ability to continue as a going concern entity by (i) negotiating other cash equity, debt or strategic financing, (ii) continuing to pursue the necessary regulatory approvals to launch commercially in the U.S. market, (iii) executing cost-cutting measures to manage operating cash spending, including the workforce " | 10-Q 2026-11-12 |
| Cash and burn | $31.5M cash; operating cash flow -$18.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 13,264,926 (2026-11-02); 137,044,440 a year earlier. 1y figure adjusted for split (1-for-12 overall). | Cover page 2026-11-02 |
| Reverse splits, 3 years | 1; latest 1-for-12 on 2026-10-05 | Source 2026-10-05 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-09-11 |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-04-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $187K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$14.2M | -$15.7M | $31.5M | $413K | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$25.5M | -$15.9M | $47.1M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | $9.2M | -$22.5M | $63.2M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | Not filed | -$43.7M | -$21.3M | $81.5M | $0 | $0 | 10-K 2026-03-24 |
| Q3 2025 2025-09-30 | Not filed | -$45.6M | -$22.7M | $77.7M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$27.9M | -$21.2M | $22.3M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2025 2025-03-31 | Not filed | -$23.7M | -$25.1M | $42.1M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2024 2024-12-31 | $3K | -$25.0M | -$17.0M | $67.5M | No debt tags | $93K | 10-K 2026-03-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-09-26 |
| Latest annual report | 10-K | 2026-03-24 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEF 14A | 2026-08-24 |
Source: SEC EDGAR submissions feed, 232 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.8% |
| 1 month | -77.5% |
| 3 months | -88.6% |
| Year to date | -96.6% |
| 1 year | -93.3% |
| From 52-week high | -96.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DRIO | DarioHealth Corp. | $1.15 | -8.73% | $13.0M |
| PAVM | PAVmed Inc. | $1.75 | +7.36% | $14.0M |
| CTSO | Cytosorbents Corporation | $4.85 | -0.41% | $15.3M |
| SNWV | SANUWAVE Health Inc. | $1.81 | -0.55% | $15.6M |
| FEMY | Femasys Inc. | $1.28 | -8.57% | $11.1M |
| RVP | Retractable Technologies Inc. | $0.5600 | +0.02% | $16.8M |
| SINT | SiNtx Technologies Inc. | $1.34 | -1.11% | $10.1M |
| CVRX | CVRx Inc. | $0.6130 | +0.92% | $17.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier